Tofacitinib – Medxy AI

Unorthodox JAK Inhibitor Dosing in Pediatric Moderate-to-Severe Alopecia Areata: A Comparative Evaluation of Tofacitinib and Baricitinib

By MedXY 03/05/2026

This study of 100 pediatric patients with moderate-to-severe alopecia areata demonstrates that unorthodox dosing regimens of tofacitinib and baricitinib provide comparable efficacy and high tolerability over 24 weeks.

Internal Medicine news Rheumatology

Tofacitinib Reverses Muscle Loss in Rheumatoid Arthritis: Insights from the RAMUS Trial

By MedXY 12/19/2025

The RAMUS study demonstrates that the JAK inhibitor tofacitinib significantly increases lower limb muscle volume in patients with rheumatoid arthritis, offering a potential explanation for associated creatinine elevations and a new therapeutic avenue for managing rheumatoid cachexia.

Internal Medicine news Rheumatology

Tofacitinib and Muscle Volume: A Potential Paradigm Shift in Managing Rheumatoid Cachexia

By MedXY 12/19/2025

The RAMUS study demonstrates that tofacitinib significantly increases lower limb muscle volume in rheumatoid arthritis patients, potentially explaining associated creatinine elevations and offering a new therapeutic avenue for combating muscle wasting.